Marseille-Kliniken AG

euro adhoc: Marseille-Kliniken AG
quarterly or semiannual financial statement / - Turnover increase to 52.8 million Euro in the first quarter of 2006/2007 - Company┬ĺs DVFA/SG adjusted result increases above-average by 0.4 million Euro to 3.6 million Eu

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc. The issuer is responsible   for the content of this announcement. --------------------------------------------------------------------------------@@end@@

08.11.2006

Berlin, 8th November 2006. The Marseille-Kliniken AG (Prime Standard, ISIN DE 0007783003, MKA)  continues improving its results in an above-average way. In the first quarter of the current financial year (01.07.2006 - 30.09.2006) the company turnover was increased to 52.8 million Euro (previous year: 51.5 million Euro). At 3.6 million Euro, the DVFA result within the company is a total of 0.4 million Euro above the level of the previous year. Per share this is equal to a result increase of 0.03 Euro to 0.30 Euro (previous year: 0.27 Euro).

The growth comes from the elderly care sector in which the turnover has increased from 39.3 million Euro in the previous year to 40.3 million Euro, which is an increase of 2.5 %. The rise is a result of the expansion of bed capacities and the utilisation increase resulting from the specialisations in stock in individual facilities. The bed capacity of the nursing sector was increased by the deadline by 474 beds to 7134 beds (previous year: 6660 beds). Therefore within the company the total capacity rose to 8612 beds (previous year: 8169 beds). At 4.2 million Euro the DVFA/SG (IFRS) adjusted result was 0.3 million Euro higher than in the previous year. The utilisation rate was increased to 92.6 % by 0.9 % points due to targeted marketing activities. So overall with 89.7 % the company┬ĺs utilisation rate was above 89.1 %, which was the level of the previous year.

The optimisation measures in the rehabilitation sector are taking hold. Although according to plan the bed capacity in this sector was reduced by 1509 beds in the previous year to now 1478 beds, the sales revenue of 12.2 million Euro has seen a slight increase by 2.5 % to 12.5 million Euro and the DVFA result with -0.6 million Euro was retained at the level of the previous year. Therefore this can be considered as a particular success, as the rehabilitation sector was burdened by the repercussions of the doctors┬ĺ strikes in the first quarter. This also explains the decrease in utilisation, which reduced from 79.2 % to 76.7 % in the remaining clinics in the quarterly comparison. The utilisation rate lies clearly above the average value of the whole year of 2005/2006 of 74.2 %.

For the rest of the financial year 2006/2007 the company is planning above-average turnover and result growth in comparison to the previous year. The already apparent positive occupancy development in the nursing sector will have great effects in the third and fourth quarters. We are consistently putting our growth strategy into action; another 1000 beds have already been contractually guaranteed. The sale of individual clinics in the rehabilitation sector will be intensively pushed. Due to the implementation of different optimisation measures from this sector the company is expecting an improvement in results.

End of the ad hoc release

@@start.t2@@end of announcement                                                 euro adhoc 08.11.2006 07:26:05
--------------------------------------------------------------------------------@@end@@

ots Originaltext: Marseille-Kliniken AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
If you have any questions please contact:

Marseille-Kliniken AG Hillermann Consulting
Axel H├Âlzer             Christian Hillermann
CEO                          Investor Relations
Alte Jakobstra├če 79/80  Eppendorfer Baum 5
10709 Berlin             20249 Hamburg
Tel.: 030 / 246 32-400 Tel.: 040 / 414 069-13
Fax: 030 / 246 32-401 Fax: 040 / 414 069-14

Branche: Pharmaceuticals
ISIN:      DE0007783003
WKN:        778300
Index:    CDAX, Classic All Share, Prime All Share
B├Ârsen:  Frankfurter Wertpapierb├Ârse / official dealing/prime standard
              B├Ârse Berlin-Bremen / free trade
              Baden-W├╝rttembergische Wertpapierb├Ârse / free trade
              B├Ârse D├╝sseldorf / free trade
              Hamburger Wertpapierb├Ârse / official dealing



Weitere Meldungen: Marseille-Kliniken AG

Das könnte Sie auch interessieren: